Jafron Biomedical Co

Jafron Biomedical Co Liabilities

The The Liabilities of Jafron Biomedical Co (300529.SZ) as of Oct 16, 2026 is 1.94 B CNY. In the previous year, The Liabilities was 2.05 B CNY — a change of -5.43% (lower).

Liabilities

1.94 BCNY

YoY

-5.43%

Last updated:

In 2025, Jafron Biomedical Co's total liabilities amounted to 1.94 B CNY, a -5.43% difference from the 2.05 B CNY total liabilities in the previous year.

The Jafron Biomedical Co Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Liabilities
Date
Liabilities
Jan 1, 2018
330.04 M CNY
Jan 1, 2019
324.13 M CNY
Jan 1, 2020
383.06 M CNY
Jan 1, 2021
1.43 B CNY
Jan 1, 2022
1.82 B CNY
Jan 1, 2023
2.39 B CNY
Jan 1, 2024
2.05 B CNY
Jan 1, 2025
1.94 B CNY
The Jafron Biomedical Co Liabilities history
YEARLiabilitiesYoY
1.94 BCNY-5.43%
2.05 BCNY-14.29%
2.39 BCNY+31.13%
1.82 BCNY+27.80%
1.43 BCNY+272.38%
383.06 MCNY+18.18%
324.13 MCNY-1.79%
330.04 MCNY+6.16%
310.90 MCNY+168.46%
115.81 MCNY-7.06%
124.61 MCNY+43.91%
86.59 MCNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Jafron Biomedical Co Stock analysis

What does Jafron Biomedical Co do? Jafron Biomedical Co Ltd is a China-based health care company headquartered in Zhuhai. The company focuses on the research, development, production, and sale of hemoperfusion products. It went public on August 2, 2016, with its stock listed under ticker 300529.SZ and ISIN CNE100002995. Jafron employs 3,003 full-time staff and operates within the health care sector. Its products include disposable hemoperfusion devices, hemoperfusion machines, disposable bilirubin adsorbers, the DX-10 blood purification machine, suture needles, and resin bandages. These products are used in treating conditions such as uremia, poisoning, severe liver diseases, autoimmune diseases, and multisystem organ failure. Jafron's products are distributed across more than 3,000 hospitals in all 31 provinces of China. The company's website is https://www.jafron.com/. Jafron Biomedical Co is one of the most popular companies on Eulerpool.

Liabilities Details

Assessing Jafron Biomedical Co's Liabilities

Jafron Biomedical Co's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Jafron Biomedical Co's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Jafron Biomedical Co's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Jafron Biomedical Co's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Jafron Biomedical Co’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Jafron Biomedical Co stock

The Liabilities of Jafron Biomedical Co is 1.94 B CNY in 2025.

The Liabilities of Jafron Biomedical Co changed from 2.05 B CNY to 1.94 B CNY, representing a -5.43% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The Liabilities Jafron Biomedical Co since 2006 – with annual values, charts, and detailed analysis.

The Liabilities's CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Liabilities's Jafron Biomedical Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Balance Sheet — Jafron Biomedical Co

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — Jafron Biomedical Co